| Literature DB >> 27998305 |
Victor Kuete1,2, Leonidah K Omosa3, Viviane R Sipowo Tala4, Jacob O Midiwo3, Armelle T Mbaveng5, Sauda Swaleh3, Oğuzhan Karaosmanoğlu6, Hülya Sivas6.
Abstract
BACKGROUND: Cancer is a major public health concern globally and chemotherapy remains the principal mode of the treatment of various malignant diseases.Entities:
Keywords: Carcinoma; Mode of action; Plumbagin; Quinones; Rapanone; cytotoxicity
Mesh:
Substances:
Year: 2016 PMID: 27998305 PMCID: PMC5175396 DOI: 10.1186/s40360-016-0104-7
Source DB: PubMed Journal: BMC Pharmacol Toxicol ISSN: 2050-6511 Impact factor: 2.483
Fig. 1Chemical structures of the tested compounds. Chrysophanol (1), emodin (2), 3,6,8-trihydroxy-1-methylanthraquinone-2-carboxylic acid methyl ester (3), a naphthaquinone; 5-hydroxy-2-methyl-1,4-naphthalenedione or plumbagin (4), benzoquinones; 2,5-dihydroxy-3-ethyl-2,5-cyclohexadiene-1,4-dione (5), 2,5-dihydroxy-3-propyl-2,5-cyclohexadiene-1,4-dione (6), 2,5-dihydroxy-3-butyl-2,5-cyclohexadiene-1,4-dione (7), 2,5-dihydroxy-3-heptyl-2,5-cyclohexadiene-1,4-dione (8), 2,5-dihydroxy-3-tridecyl-2,5-cyclohexadiene-1,4-dione or rapanone (9), 2,5-dihydroxy-3-pentadecyl-2,5-cyclohexadiene-1,4-dione (10), 2-hydroxy-5-methoxy-3-undecyl-1,4-benzoquinone, 5-O-methylembelin (11), 2,5 dimethoxy-6-(14-nonadecenyl)-1,4-benzoquinone (12), 1,2,4,5-tetraacetate-3-methyl-6-(14-nonadecenyl)-cyclohexadi-2,5-diene (13), ardisiaquinone B (14)
Cytotoxicity of tested compounds and doxorubicin towards cancer cell lines and normal cells as determined by the neutral red assay
| Compounds | Cell lines, IC50 values in μM and selectivity indexa (in bracket) | ||||||
|---|---|---|---|---|---|---|---|
| A549 | SPC212 | DLD-1 | Caco-2 | MCF-7 | HepG2 | CRL2120 | |
| 1 | 52.24 ± 5.51 (>3.01) | 145.63 ± 10.63 (>1.08) | >157.48 | >157.48 | >157.48 | >157.48 | >157.48 |
| 2 | 66.30 ± 6.19 (>2.23) | 99.31 ± 8.46 (>1.49) | 77.28 ± 8.77 (>1.92) | 73.63 ± 3.52 (>2.01) | 37.57 ± 2.59 (>3.94) | 71.7 ± 4.52 (>2.07) | >148.15 |
| 3 | >121.95 | >121.95 | >121.95 | >121.95 | >121.95 | >121.95 | >121.95 |
| 4 |
|
|
|
|
|
| 67.66 ± 6.49 |
| 5 | >238.10 | >238.10 | >238.10 | >238.10 | >238.10 | >238.10 | 95.51 ± 5.64 |
| 6 | >222.22 | >222.22 | >222.22 | >222.22 | 161.92 ± 11.37 | >222.22 | >222.22 |
| 7 | 68.62 ± 7.55 ((>2.97) | 87.91 ± 5.66 (2.32) | >204.08 | 89.72 ± 8.80 (>2.27) | 64.59 ± 13.42 (>3.16) | 176.17 ± 28.5 (>1.16) | >204.08 |
| 8 | 107.52 ± 17.95 (1.09) |
| >168.07 | 63.93 ± 5.97 (2.27) | 38.8 ± 3.33 (3.16) | 94.22 ± 2.7 (1.16) | 117.27 ± 1.22 |
| 9 | 27.35 ± 1.46 (3.48) |
| 46.62 ± 5.38 (2.04) | 22.95 ± 0.13 (4.15) | 16.94 ± 4.65 (5.62) | 32.69 ± 0.61 (2.91) | 95.24 ± 6.65 |
| 10 | 43.32 ± 2.72 (>2.87) |
| 51.21 ± 5.54 (>2.43) | 27.81 ± 2.03 (>4.47) | 30.37 ± 8.64 (>4.09) | 48.35 ± 3.73 (>2.57) | >124.24 |
| 11 | 50.26 ± 2.60 (0.88) | 38.28 ± 3.23 (1.15) | 45.37 ± 4.89 (0.97) | 38.89 ± 2.35 (1.14) | 22.56 ± 1.57 (1.96) | 61.28 ± 5.53 (0.72) | 44.20 ± 0.2 |
| 12 | >129.45 | >129.45 | >129.45 | >129.45 | >129.45 | >129.45 | >129.45 |
| 13 | 47.53 ± 3.56 (1.96) | 36.21 ± 3.08 (2.57) | 25.09 ± 1.50 (3.72) | 24.63 ± 2.71 (3.78) |
| 18.17 ± 1.46 (5.13) | 93.21 ± 1.17 |
| 14 | 21.68 ± 1.50 (3.29) |
| 114.17 ± 3.68 (0.62) | >123.08 | >123.08 | 114.60 ± 4.29 (0.62) | 71.34 ± 5.23 |
| Doxorubicin |
|
|
|
|
|
|
|
(a): The selectivity index was determined as the ratio of IC50 value in the CRL2120 normal fibroblasts divided by the IC50 in the cancer cell lines. Chrysophanol (1), emodin (2), 3,6,8-trihydroxy-1-methylanthraquinone-2-carboxylic acid methyl ester (3), plumbagin (4), 2,5-dihydroxy-3-ethyl-2,5-cyclohexadiene-1,4-dione (5), 2,5-dihydroxy-3-propyl-2,5-cyclohexadiene-1,4-dione (6), 2,5-dihydroxy-3-butyl-2,5-cyclohexadiene-1,4-dione (7), 2,5-dihydroxy-3-heptyl-2,5-cyclohexadiene-1,4-dione (8), 2,5-dihydroxy-3-tridecyl-2,5-cyclohexadiene-1,4-dione or rapanone (9), 2,5-dihydroxy-3-pentadecyl-2,5-cyclohexadiene-1,4-dione (10), 2-hydroxy-5-methoxy-3-undecyl-1,4-benzoquinone, 5-O-methylembelin (11), 2,5 dimethoxy-6-(14-nonadecenyl)-1,4-benzoquinone (12), 1,2,4,5-tetraacetate-3-methyl-6-(14-nonadecenyl)-cyclohexadi-2,5-diene (13), ardisiaquinone B (14). In bold: significant activity [3, 21, 22, 25]
Fig. 2Effects of plumbagin (4), rapanone (9), and doxorubicin on cell cycle distribution in MCF-7 cells. IC50 values were 0.06 μM (4), 16.94 (9) and 0.35 μM (doxorubicin)
Fig. 3Effects of plumbagin (4), rapanone (9), and doxorubicin on MMP in MCF-7 cells for 72 h. IC50 values were 0.06 μM (4), 16.94 (9) and 0.35 μM (doxorubicin). Cells were treated with ¼ × IC50 (C1), ½ × IC50 (C2) and IC50 (C3) of each compound
Fig. 4Induction of ROS in MCF-7 cells after treatment with plumbagin (4), rapanone (9), and doxorubicin for 24 h. IC50 values were 0.06 μM (4), 16.94 (9) and 0.35 μM (doxorubicin). Cells were treated with ¼ × IC50 (C1), ½ × IC50 (C2) and IC50 (C3) of each compound